TrialInternational journal of rheumatic diseases2023

Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.

Hisashi Yamanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.